Infectious DiseaseVascular Surgery
Diabetic Foot Infection
IDSA / IWGDF — severity classification, multidisciplinary foot team, antibiotic + surgical, osteomyelitis recognition.
Source: IWGDF 2023; NICE NG19
Step 1 of ~3
info
Recognise + Classify
Diabetic foot ulcer + ≥2 signs of inflammation (erythema, warmth, swelling, pain, purulence). IWGDF classification:
• Mild: limited cellulitis ≤2 cm around ulcer; superficial.
• Moderate: deeper / extensive (>2 cm); or with abscess / osteomyelitis / fasciitis but no systemic features.
• Severe: systemic toxicity / sepsis / shock.
Probe-to-bone test: positive suggests osteomyelitis. Plain XR + MRI for osteomyelitis confirmation.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Linezolid (MRSA Osteomyelitis) · Oxazolidinone Antibiotic
- Ciprofloxacin (Orthopaedic — Gram-negative Osteomyelitis) · Fluoroquinolone Antibiotic
- Flucloxacillin (Burns — Wound Infection) · Antibiotic — Penicillinase-Resistant Penicillin
- Colistin (Polymyxin E — XDR Burns Infection) · Antibiotic — Polymyxin (Last-Resort)
- Cefazolin (Surgical Prophylaxis) · 1st Generation Cephalosporin (Surgical Antibiotic Prophylaxis)
- Clindamycin (Surgical Prophylaxis — Penicillin Allergy) · Antibiotic (Lincosamide) — Surgical Prophylaxis
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023
Decision support only. Always apply local guidelines and clinical judgement.